Aligos Therapeutics, Inc. ALGS
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Aligos Therapeutics, Inc. (ALGS) is a healthcare company listed in the US with a market value of about $13M. In the twelve months to September 30, 2026 it had revenue of $6M and net income of -$66M, a net margin of -1137.2%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -76%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 91% below the current price.
About Aligos Therapeutics
Aligos Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 480% over three years (dilution for shareholders). It spends 3177% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $2M | $4M | $6M | $0 | $0 | $0 | — |
| Net income | -$66M | -$24M | -$131M | -$88M | -$96M | -$128M | -$109M | -$52M |
| Free cash flow | — | — | -$81M | -$79M | -$80M | -$117M | -$76M | -$50M |
| EPS (diluted) | $-6.45 | $-2.45 | $-20.94 | $-34.20 | $-56.40 | $-80.72 | $-272.49 | $-652.77 |
| Net margin | -1137.2% | -1106.7% | -3633.7% | -1416.2% | — | — | — | — |
| ROIC | — | -118.5% | — | -67.6% | -66.4% | -51.0% | -33.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Aligos Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 91% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Aligos Therapeutics pay a dividend?
Not currently.
Is Aligos Therapeutics a good stock to buy?
We do not give buy or sell advice. Aligos Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.